Last reviewed · How we verify
CsA+Herombopag
CsA (cyclosporine A) suppresses T-cell activation while herombopag stimulates thrombopoietin receptors to increase platelet production, together addressing immune-mediated thrombocytopenia.
CsA (cyclosporine A) suppresses T-cell activation while herombopag stimulates thrombopoietin receptors to increase platelet production, together addressing immune-mediated thrombocytopenia. Used for Immune thrombocytopenia (ITP).
At a glance
| Generic name | CsA+Herombopag |
|---|---|
| Also known as | NSAA group intervention treatment |
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Combination therapy: calcineurin inhibitor + thrombopoietin receptor agonist |
| Target | Calcineurin (CsA); thrombopoietin receptor / MPL (herombopag) |
| Modality | Small molecule |
| Therapeutic area | Hematology / Immunology |
| Phase | FDA-approved |
Mechanism of action
Cyclosporine A is a calcineurin inhibitor that reduces T-cell proliferation and cytokine production, addressing the autoimmune component of thrombocytopenia. Herombopag is a thrombopoietin receptor agonist that directly stimulates megakaryopoiesis to increase platelet counts. The combination targets both the immune destruction of platelets and the bone marrow's platelet-producing capacity.
Approved indications
- Immune thrombocytopenia (ITP)
Common side effects
- Nephrotoxicity (cyclosporine-related)
- Hypertension
- Infection risk (immunosuppression)
- Headache
- Gastrointestinal disturbance
Key clinical trials
- Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia (PHASE2)
- Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia (PHASE2)
- Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia (PHASE2)
- Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System (PHASE4)
- A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CsA+Herombopag CI brief — competitive landscape report
- CsA+Herombopag updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI